about
Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patientsMGMT gene silencing and benefit from temozolomide in glioblastoma.Cloning and characterization of the expression pattern of a novel splice product MIA (splice) of malignant melanoma-derived growth-inhibiting activity (MIA/CD-RAP) [corrected]Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal originInhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniquesExpression levels of melanoma inhibitory activity correlate with time to progression in patients with high-grade gliomaDiabetes, use of antidiabetic drugs, and the risk of gliomaNew aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cellsROC analysis as an additional method to characterize time to event data.Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2.EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial.Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma.High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial.RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II studyAdvanced MRI and PET imaging for assessment of treatment response in patients with gliomas.Response-predictive gene expression profiling of glioma progenitor cells in vitro.Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers.Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009.Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb studyTranscranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results.Lactate-modulated induction of THBS-1 activates transforming growth factor (TGF)-beta2 and migration of glioma cells in vitroIbuprofen and Diclofenac Restrict Migration and Proliferation of Human Glioma Cells by Distinct Molecular Mechanisms.Inventory of a Neurological Intensive Care Unit: Who Is Treated and How Long?Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of GliomaValidation Study: Response-Predictive Gene Expression Profiling of Glioma Progenitor Cells In VitroThe cancer stem cell subtype determines immune infiltration of glioblastoma.Aberrant expression of c-Jun in glioblastoma by internal ribosome entry site (IRES)-mediated translational activationTGF-ß isoforms in cancer: Immunohistochemical expression and Smad-pathway-activity-analysis in thirteen major tumor types with a critical appraisal of antibody specificity and immunohistochemistry assay validity.Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trialMGMT methylation status: the advent of stratified therapy in glioblastoma?Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.High-grade glioma: refined diagnostics steering stratified therapy.Metformin inhibits proliferation and migration of glioblastoma cells independently of TGF-β2.Procarbazine--a traditional drug in the treatment of malignant gliomas.Rechallenge with temozolomide in patients with recurrent gliomas.Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides.Metabolic syndrome in relation to risk of meningioma.Early postoperative tumor progression predicts clinical outcome in glioblastoma-implication for clinical trials.TGF-β2 signaling in high-grade gliomas.
P50
Q26853308-0033EB23-C1B1-4257-97BB-54DA2B85A722Q27824832-BD238686-2080-4A1B-A570-C5F4890FE344Q28201746-A67CB777-49EB-4B81-B38E-52F21EC63314Q28217739-45507154-87D6-46B5-87E4-137580CD1B1FQ28283735-6C40EAAF-1C0C-4CC9-8C05-DD5A232526E7Q28293817-B6C33331-6E33-4FC0-AD12-2406F0D691B5Q28387952-E680384A-CB9F-4749-BBAF-5C9E4CA6FF8CQ28534587-1AE7671E-9F08-42DB-9D10-439A729A2FB2Q30986133-B694AA40-8FA1-4DE9-942D-D2262121E8C8Q33387162-66B702D9-0C1C-4123-BB7D-00950E071DB3Q33387221-B73D02F4-D6C5-470D-8CA4-5D9F9F4C44CEQ33417361-8F147C9A-C650-40B5-B0E3-E8E82460249DQ33426222-0CBC41A6-9A1D-4BCF-BF78-0E535A8B74BCQ33434270-BA10BCD5-79A6-4FA3-A845-EFE317B0E728Q33499541-A974CB0F-7120-4618-867D-439ACA057EE0Q33655854-8F5CBAE0-4F4D-45D0-9489-21958C331658Q34277599-F451D3DC-AA0E-4955-866B-52AF71BFF34BQ34290211-60AEF791-A4A8-44F7-A2A8-7E299918E650Q34479492-586FD476-BD11-45CC-868E-C35BC37E0994Q34480536-35A6B838-FAC4-4FD5-851E-9A8AED48EC2BQ34615214-635B3C80-665D-415E-BAF2-639611BC5F26Q35041092-C9EE5D28-9B7E-4631-AB71-1A4F1344B439Q35814510-FFA2056F-631B-4783-917B-4C7DE4729F31Q35829467-9A4D2759-B7D4-488F-AE7D-EE8AD260CC0FQ35922107-BFECBCB7-F9D3-4B3A-A27F-D451419C7C4CQ35957639-1A3FD719-AE95-4C5D-B621-6ECE32EB9F06Q36297010-4D27A749-2968-4B78-94FF-CA24AD5EC615Q36342526-B57C23FE-817E-4E1D-9838-DD574B2D8090Q36413606-E378D0D7-3707-456D-B91A-B7302C13059FQ36705933-318EE6ED-9FA2-4695-8DCF-0DF8D179BAFAQ36746220-DFAD49E1-47BE-4174-8326-C96BE0672692Q36887193-00486618-6638-4D61-A388-1BB81E1E23B5Q37057957-FEFD5EEC-0DC8-43CF-86A1-C6D3C45396C9Q37118676-45EDA05B-930A-4F21-B8AA-B7B1AF72DA48Q37184947-E091E60D-92BA-42D7-9EE4-11A0172177CDQ37400645-EA92CFD4-9E6C-4D88-8776-721A2B817F32Q37628708-BAC5496A-17B5-4B39-8C63-89A0C7B8E4FBQ37709266-092D1625-FECA-45D0-8DFF-376B2C2B1325Q37736028-E696B8AE-71F5-4478-8193-E7271DBE75DCQ37880953-7B64D629-FC6B-476C-82DE-77450D67BAC5
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Peter Hau
@ast
Peter Hau
@en
Peter Hau
@es
Peter Hau
@nl
Peter Hau
@sl
type
label
Peter Hau
@ast
Peter Hau
@en
Peter Hau
@es
Peter Hau
@nl
Peter Hau
@sl
prefLabel
Peter Hau
@ast
Peter Hau
@en
Peter Hau
@es
Peter Hau
@nl
Peter Hau
@sl
P214
P106
P21
P214
P31
P496
0000-0003-3894-5053
P735
P7859
viaf-67353236